Anthony J. Olszanski

Wistar Institute

$599,481

Attributed

$1,198,962

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $410.3K · FY2021–24

$500K$375K$250K$125K$0

'21

'22

'23

'24

Funding mix

By agency

NIH$1,198,962 · 2

By mechanism

R01$726,554 · 1

R21$472,408 · 1

Top collaborators

Dario C. Altieri2 shared
Igor Astsaturov2 shared

Most similar at Wistar Institute

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Safety”

Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Kimberly Smith · Ppd Development Lp$122,008,792
Klaus Romero · Critical Path Institute$90,404,592
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611

Research focus

SafetyIntravenous AdministrationProteinsSmall MoleculePathway InteractionsBiopsyMalignant NeoplasmsPhase I Clinical TrialsSignal TransductionTumorResponsePharmaceutical PreparationsBiological MarkersBiologicalAntineoplastic AgentsBioenergeticsBiochemicalAnticancer ActivityAnimalsCellsCell NucleusBindingCell SurvivalCancer Therapy

Grant awards (4)

A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma$208,738

R21 · FY2024 · CA

A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma$263,670

R21 · FY2023 · CA

A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib$316,269

R01 · FY2022 · CA

A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib$410,285

R01 · FY2021 · CA